In all AML cell lines, 2‐days treatment with increasing concentrations of PT2385 induced a dose‐dependent reduction in cell counts (Figs 4A and EV3A) and a concordant increase in CD11b+ cells (Figs 4B and EV3B) in the absence of cell death (Fig EV3C). The gene discussed is ITGAM; the disease is acute myeloid leukemia.